The Lancet9h
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta
The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...
Precision gene therapy for liver disorders increases number of correctly repaired cells
Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
Investor's Business Daily on MSN1d
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.
Vertex's Revenue Surges but EPS Slips
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
The drugmaker is looking to its acute pain drug, Journavx, to drive growth beyond its established line of cystic fibrosis ...
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...